Sacituzumab govitecan vs docetaxel in patients with mNSCLC non-responsive to last anti-PD-(L)1containing regimen: EVOKE-01
Authors
Garassino, M. C.Juan-Vidal, O.
Felip, E.
Girard, N.
Dols, M. C.
Haggstrom, D. E.
Reinmuth, N.
Tiseo, M.
Hochmair, M. J.
Summers, Yvonne
Hendriks, L. E. L.
Daniel, D. B.
Kato, T.
Cheema, P.
Mekan, S.
Patel, R.
Zhang, E.
Paz-Ares, L. G.
Affiliation
The Christie NHS Foundation Trust, Manchester, UKIssue Date
2024